Immune Design Corp (NASDAQ:IMDZ) traded down 7.5% on Friday . The company traded as low as $3.60 and last traded at $3.70. 507,371 shares traded hands during mid-day trading, a decline of 7% from the average session volume of 544,419 shares. The stock had previously closed at $4.00.
A number of equities research analysts have recently weighed in on the stock. Zacks Investment Research lowered shares of Immune Design from a “buy” rating to a “hold” rating in a report on Monday, January 8th. Cowen restated a “buy” rating on shares of Immune Design in a report on Monday, December 11th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. Immune Design currently has an average rating of “Hold” and an average target price of $13.06.
In other news, major shareholder Leo Guthart bought 20,000 shares of the firm’s stock in a transaction that occurred on Monday, January 8th. The shares were bought at an average cost of $3.90 per share, with a total value of $78,000.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Carlos V. Paya sold 7,970 shares of Immune Design stock in a transaction on Friday, January 5th. The stock was sold at an average price of $4.17, for a total transaction of $33,234.90. Following the completion of the transaction, the chief executive officer now directly owns 114,560 shares in the company, valued at $477,715.20. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 13,959 shares of company stock valued at $58,209. Company insiders own 20.70% of the company’s stock.
WARNING: This story was first posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this story on another site, it was illegally copied and reposted in violation of U.S. and international copyright laws. The correct version of this story can be viewed at https://www.tickerreport.com/banking-finance/3255938/immune-design-imdz-trading-down-7-5.html.
Immune Design Company Profile
Immune Design Corp. is a clinical-stage immunotherapy company. The Company is focused on cancer with in vivo approaches designed to enable the body’s immune system to fight disease. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (CTLs) to fight cancer.
Receive News & Ratings for Immune Design Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design and related companies with MarketBeat.com's FREE daily email newsletter.